Matthew Labenski

1.7k total citations
20 papers, 701 citations indexed

About

Matthew Labenski is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Matthew Labenski has authored 20 papers receiving a total of 701 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 9 papers in Oncology and 7 papers in Organic Chemistry. Recurrent topics in Matthew Labenski's work include Peptidase Inhibition and Analysis (7 papers), Click Chemistry and Applications (5 papers) and Neuropeptides and Animal Physiology (5 papers). Matthew Labenski is often cited by papers focused on Peptidase Inhibition and Analysis (7 papers), Click Chemistry and Applications (5 papers) and Neuropeptides and Animal Physiology (5 papers). Matthew Labenski collaborates with scholars based in United States, India and Switzerland. Matthew Labenski's co-authors include William Westlin, Russell Karp, Russell C. Petter, Juswinder Singh, Prasoon Chaturvedi, Mariana Nacht, Michael P. Sheets, Zhendong Zhu, Lyn H. Jones and Christina M. Woo and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Biochemistry.

In The Last Decade

Matthew Labenski

20 papers receiving 686 citations

Peers

Countries citing papers authored by Matthew Labenski

Since Specialization

Citations

This map shows the geographic impact of Matthew Labenski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Labenski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Labenski more than expected).

Fields of papers citing papers by Matthew Labenski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Labenski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Labenski. The network helps show where Matthew Labenski may publish in the future.

Co-authorship network of co-authors of Matthew Labenski

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Labenski. A scholar is included among the top collaborators of Matthew Labenski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Labenski. Matthew Labenski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	SMaSh: A Streptavidin Mass Shift Assay for Rapidly Quantifying Target Occupancy by Irreversible Inhibitors 2021 ·Biochemistry ·Matthew Labenski, Leslie A. Bateman, (unknown), (unknown), (unknown), Lixin Qiao, (unknown)	2
2	Labeling Preferences of Diazirines with Protein Biomolecules 2021 ·Journal of the American Chemical Society ·(unknown), Giovanni Muncipinto, Hung‐Yi Wu, Andrew C. Huang, Matthew Labenski, Lyn H. Jones, Christina M. Woo	133
3	S-adenosyl-l-methionine protection of acetaminophen mediated oxidative stress and identification of hepatic 4-hydroxynonenal protein adducts by mass spectrometry 2014 ·Toxicology and Applied Pharmacology ·James M. Brown, (unknown), (unknown), Matthew Labenski, (unknown), John G. Ball, Serrine S. Lau, Monica Valentovic	15
4	Metabolites of PPI-2458, a Selective, Irreversible Inhibitor of Methionine Aminopeptidase-2: Structure Determination and In Vivo Activity 2013 ·Drug Metabolism and Disposition ·Christopher C. Arico-Muendel, Bruce Belanger, Dennis R. Benjamin, (unknown), (unknown), Jennifer L. DeLorey, (unknown), Ulrike Gradhand, (unknown), Susan E. Hill, Matthew Labenski, Barry A. Morgan, Gary O’Donovan, Kavirayani R. Prasad, Steven R. Skinner, (unknown), Charles D. Thompson, James Wakefield, William Westlin, Kerry White	9
5	Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans 2013 ·Journal of Pharmacology and Experimental Therapeutics ·Erica N Evans, Richland Tester, (unknown), Russell Karp, Michael P. Sheets, Matthew Labenski, Steven R. Witowski, Heather Lounsbury, Prasoon Chaturvedi, Hormoz Mazdiyasni, Zhendong Zhu, Mariana Nacht, Martin I. Freed, Russell C. Petter, (unknown), Juswinder Singh, William Westlin	171
6	Orally Active Fumagillin Analogues: Transformations of a Reactive Warhead in the Gastric Environment 2013 ·ACS Medicinal Chemistry Letters ·Christopher C. Arico-Muendel, (unknown), Dennis R. Benjamin, (unknown), Paolo A. Centrella, Jennifer L. DeLorey, (unknown), (unknown), Matthew Labenski, Barry A. Morgan, Gary O’Donovan, Amy A. Sarjeant, Steven R. Skinner, Charles D. Thompson, (unknown), William Westlin, Kerry White	7
7	Discovery of a Potent and Isoform-Selective Targeted Covalent Inhibitor of the Lipid Kinase PI3Kα 2013 ·Journal of Medicinal Chemistry ·Mariana Nacht, Lixin Qiao, Michael P. Sheets, Thia St Martin, Matthew Labenski, Hormoz Mazdiyasni, Russell Karp, Zhendong Zhu, Prasoon Chaturvedi, Deepa Bhavsar, Deqiang Niu, William Westlin, Russell C. Petter, (unknown), Juswinder Singh	73
8	The Frequency of 1,4-Benzoquinone-Lysine Adducts in Cytochrome c Correlate with Defects in Apoptosome Activation 2011 ·Toxicological Sciences ·(unknown), Matthew Labenski, Srinivas Malladi, J. D. Chapman, Shawn B. Bratton, Terrence J. Monks, Serrine S. Lau	11
9	Identification of Chemical-Adducted Proteins in Urine by Multi-dimensional Protein Identification Technology (LC/LC–MS/MS) 2010 ·Methods in molecular biology ·Matthew Labenski, (unknown), Terrence J. Monks, Serrine S. Lau	1
10	One-Dimensional Western Blotting Coupled to LC-MS/MS Analysis to Identify Chemical-Adducted Proteins in Rat Urine 2010 ·Methods in molecular biology ·Matthew Labenski, (unknown), Terrence J. Monks, Serrine S. Lau	2
11	Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine 2010 ·Nature Chemical Biology ·Margit Hagel, Deqiang Niu, Thia St Martin, Michael P. Sheets, Lixin Qiao, Hugues Bernard, Russell Karp, Zhendong Zhu, Matthew Labenski, Prasoon Chaturvedi, Mariana Nacht, William Westlin, Russell C. Petter, Juswinder Singh	77
12	Utilization of MALDI-TOF to Determine Chemical-Protein Adduct Formation In Vitro 2010 ·Methods in molecular biology ·(unknown), Matthew Labenski, Terrence J. Monks, Serrine S. Lau	2
13	Utilization of LC-MS/MS Analyses to Identify Site-Specific Chemical Protein Adducts In Vitro 2010 ·Methods in molecular biology ·(unknown), Matthew Labenski, Terrence J. Monks, Serrine S. Lau	2
14	764 AVL-181, A POTENT AND SELECTIVE IRREVERSIBLE HCV PROTEASE INHIBITOR, REQUIRES A HELPER AMINO ACID IN THE BINDING MICROENVIRONMENT TO FORM A COVALENT BOND WITH CYS-159 2010 ·Journal of Hepatology ·(unknown), Margit Hagel, Lixin Qiao, Thia St Martin, Michael P. Sheets, Prasoon Chaturvedi, Matthew Labenski, Mariana Nacht, William Westlin, Russell C. Petter, Juswinder Singh	2
15	Protein Electrophile-Binding Motifs: Lysine-Rich Proteins Are Preferential Targets of Quinones 2009 ·Drug Metabolism and Disposition ·Matthew Labenski, (unknown), (unknown), Terrence J. Monks, Serrine S. Lau	23
16	An inhibitor of methionine aminopeptidase type-2, PPI-2458, ameliorates the pathophysiological disease processes of rheumatoid arthritis 2008 ·Inflammation Research ·Douglas Lazarus, (unknown), (unknown), (unknown), Matthew Labenski, James Wakefield, Russell Karp, (unknown), (unknown), Jennifer Hoyt, Charles D. Thompson, Gerhard Hannig, William Westlin	11
17	Quinone Electrophiles Selectively Adduct “Electrophile Binding Motifs” within Cytochrome c 2007 ·Biochemistry ·(unknown), Matthew Labenski, Srinivas Malladi, Vijay Gokhale, (unknown), Rania S. Milleron, Shawn B. Bratton, Terrence J. Monks, Serrine S. Lau	50
18	Inhibition of melanoma tumor growth by a pharmacological inhibitor of MetAP-2, PPI-2458 2006 ·International Journal of Oncology ·Gerhard Hannig, Douglas Lazarus, Sylvie G. Bernier, Russell Karp, (unknown), (unknown), Matthew Labenski, (unknown), Charles D. Thompson, William Westlin	14
19	A Novel Methionine Aminopeptidase-2 Inhibitor, PPI-2458, Inhibits Non–Hodgkin's Lymphoma Cell Proliferation In vitro and In vivo 2006 ·Clinical Cancer Research ·(unknown), Russell Karp, (unknown), (unknown), Jennifer Hoyt, Matthew Labenski, Michael J. Murray, Gerhard Hannig, William Westlin, Charles D. Thompson	12
20	A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis 2004 ·Proceedings of the National Academy of Sciences ·Sylvie G. Bernier, Douglas Lazarus, (unknown), (unknown), Matthew Labenski, Charles D. Thompson, William Westlin, Gerhard Hannig	84

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact